Evaluation of PSA Blood Levels Prior to and After Digital Rectal Examination
NCT ID: NCT02747563
Last Updated: 2016-04-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
60 participants
INTERVENTIONAL
2016-05-31
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Alpha Blockers on Prostate-specific Antigen (PSA) Change in Men With Lower Urinary Tract Symptoms (LUTS)
NCT01250483
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
NCT00037141
Study of Median Lobe Prostatic UroLift Procedure
NCT02625545
The Influence of Benign Prostatic Hyperplasia on Bladder Function
NCT03098147
PSA Glycomics Assay for Early Detection of Prostate Cancer
NCT04393376
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The change of PSA will be evaluated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Surveillance
Patients with known prostate cancer eligible for active surveillance Intervention - PSA measurement
Blood test (PSA)
Measurement of blood PSA levels
Controls
Patients without known diagnosis of prostate cancer Intervention - PSA measurement
Blood test (PSA)
Measurement of blood PSA levels
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood test (PSA)
Measurement of blood PSA levels
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Intact Rectum
* Prostate Cancer eligible for active surveillance
Exclusion Criteria
* Under Androgen Deprivation Therapy
* Prior prostate surgery
18 Years
99 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kaplan Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Uri Lindner
Dr. Uri Lindner, Staff Urologist, Kaplan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaplan Medical Center
Rehovot, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0210-15-KMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.